The observed clinical efficacy of mTORC1 inhibitors in patients with renal cell carcinoma may be mediated in part by dependence of efficient HIF translation on the mTOR pathway by intercepting the VEGF/VEGFR and/or PDGF/PDGFR signalling cascades. This evidence concerns the gene VEGFA and hereditary clear cell renal cell carcinoma.